Small intestine adenocarcinoma

MONDO:0003198

An adenocarcinoma that arises from the small intestine. Histologic variants include mucinous adenocarcinoma and signet ring cell carcinoma.

Also known as: adenocarcinoma - small intest., adenocarcinoma of small bowel, adenocarcinoma of small intestine, adenocarcinoma of the small bowel, adenocarcinoma of the small intestine, small bowel adenocarcinoma, small intestinal adenocarcinoma, small intestine adenocarcinoma

2933 clinical trials for this condition and its sub-types, 18 tagged with Small intestine adenocarcinoma itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Adenocarcinoma (5262) ↑ Small intestine carcinoma (105)

Sub-types of Small intestine adenocarcinoma

Duodenal adenocarcinoma 9 trials · 44 incl. sub-types
1 sub-type
- Ampulla of vater adenocarcinoma 11 trials · 42 incl. sub-types Sub-types →
Jejunal adenocarcinoma 0 trials

Most studied deeper sub-types

Periampullary adenocarcinoma (33) Ampulla of vater clear cell adenocarcinoma (0) Ampulla of vater mucinous adenocarcinoma (0) Ampullary signet ring cell adenocarcinoma (0)

Including sub-types (2933) Tagged with Small intestine adenocarcinoma (18)

Trials to join now! 10 Not yet recruiting 1 Not yet finished but already full! 4 Completed 3

Can a TROP2-targeting drug shrink hard-to-treat small bowel cancer?

Disease control Not yet recruiting

This phase II trial tests whether sacituzumab tirumotecan, an antibody-drug conjugate that targets the TROP2 protein, can shrink tumors in people with advanced small bowel adenocarcinoma that has worsened after platinum-based chemotherapy. About 27 adults with this rare cancer wi…

Phase 2 • Sponsor: National Cancer Center, Japan • Aim: Disease control

Last updated Jul 24, 2026 00:00 UTC

Small intestine adenocarcinoma

Where it sits in the disease tree

Most studied deeper sub-types

Can a TROP2-targeting drug shrink hard-to-treat small bowel cancer?